Aduro Biotech (ADRO) Tops Q4 EPS by 19c

Aduro Biotech (NASDAQ: ADRO) reported Q4 EPS of $0.04, $0.19 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $34.38 million versus the consensus estimate of $15.4 million.

For earnings history and earnings-related data on Aduro Biotech (ADRO) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Workhorse Group (WKHS) Misses Q2 EPS by 77c